This blog is based on Frost & Sullivan’s “Frost Radar™: Antibody-drug Conjugate Contract Development and Manufacturing Organizations, 2025,” authored by Unmesh Lal, Vice President, Healthcare & Life Sciences Practice.
Antibody-drug conjugates (ADCs) are precision therapies designed to destroy cancer cells by combining targeted antibodies with powerful chemical payloads. Developing and manufacturing these complex therapies is no small feat, everything from antibody production and payload synthesis to conjugation, testing, and final formulation requires specialized expertise.
Today, ADCs have become more sophisticated, fragmented supply chains, strict regulatory requirements, and the need for careful handling of highly potent compounds are driving many companies to rely on experienced contract development and manufacturing organization (CDMO) partners. At the same time, the global ADC market is set to grow at a 19% CAGR through 2030, fueled by a strong pipeline and expanding approvals.
Transform Your ADC Strategy
Discover how integrated CDMO services, advanced technologies, and next-generation conjugates are reshaping ADC manufacturing in Frost & Sullivan’s latest podcast.
To capitalize on this shift, leading CDMOs are turning to advanced analytics, proprietary manufacturing platforms, and next-generation capabilities like site-specific ADCs, antibody-oligonucleotide conjugates (AOCs), and antibody-radionuclide conjugates (ARCs). These integrated solutions help companies develop complex therapies faster, scale efficiently, and maintain high product quality across the evolving ADC landscape.
Is your ADC strategy aligned with the latest integrated CDMO capabilities and next-generation conjugates?
What’s Driving Transformation in the ADC CDMO Ecosystem?
Disruptive Technologies
ADCs are complex molecules composed of a monoclonal antibody, a chemical linker, and a highly potent cytotoxic payload, making manufacturing technically demanding. In response, leading ADC CDMOs are developing proprietary conjugation platforms and applying advanced process analytics to improve yield, consistency, and release speed.
Transformative Megatrends
With rapid growth driven by rising regulatory approvals and a strong clinical pipeline, ADCs are transforming cancer treatment and shifting from a niche modality to a core component of oncology portfolios. This momentum is reshaping investment priorities, capacity expansion, and partnership strategies across the biopharma value chain.
Geopolitical Chaos
Geopolitical tensions and supply chain disruptions are exposing vulnerabilities in globally distributed ADC CDMO manufacturing networks. In response, CDMOs and sponsors are prioritizing regional manufacturing, added redundancy, and stronger operational resilience to reduce risk and ensure continuity.
So, which digital strategies and operating models will help your organization scale amid these transformative forces?
The ADC CDMO Transformation at a Glance
The Competitive Landscape: Who’s Leading the Charge in ADC CDMOs?
The global ADC CDMO landscape is evolving rapidly, with a group of specialized players leading the way in innovation, scale, and execution across complex oncology manufacturing programs.
What Makes Them Stand Out?
- Dedicated ADC Facilities: Good Manufacturing Practices (GMP)-compliant, purpose-built suites with 50L to 200L reactors and high-containment levels (OEB 4 to 5).
- Technology Leadership: Proprietary site-specific conjugation platforms, advanced payload-linker libraries, and real-time analytical monitoring.
- Strategic Commitment: Major CAPEX investments, strong parent company backing, and consistent revenue growth in the biologics CDMO segment.
Among the 15 companies featured in the Frost Radar™, we have highlighted three standout players shaping the future of ADC manufacturing:
- Abzena leverages its ThioBridge® conjugation platform to create site-specific, more homogeneous ADCs with precise drug-to-antibody ratios. Its integrated model reduces tech-transfer risks and speeds up the process from early development to late-stage manufacturing.
- Ajinomoto Bio-Pharma Services stands out with proprietary microbial expression systems and high-potency aseptic fill-finish capabilities. By pairing advanced containment with digitally integrated quality systems, it delivers reliable execution across multistep ADC programs.
- Axplora provides end-to-end capabilities, from payload-linker synthesis and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) to bioconjugation, under one roof. Its strong track record in clinical and commercial ADC production makes it a preferred partner for sponsors seeking manufacturing resilience in Europe
Do you have the right tools to benchmark performance and identify partners proven in ADC innovation?
Best Practices for Scaling ADC Manufacturing
As CDMOs evolve from traditional capacity providers into technology-driven partners, they are navigating rapid changes in ADC design while working to align capabilities across global networks. Considering these developments, the following best practices can help organizations move faster and create stronger value for their clients:
- Integrated Service Models: Combine proprietary platforms with hands-on expertise to boost performance and enable more collaborative CDMO partnerships.
- Site-specific ADC Conjugation: Focus on precision conjugation methods that create more uniform ADCs and maintain predictable drug-to-antibody ratios.
- Supply Chain Diversification and Digital Integration: Expand manufacturing across global networks to better support end-to-end development and production needs.
Can your organization execute these best practices at clinical and commercial scale?
Emerging Opportunities in ADC CDMO
As novel modalities gain momentum and clients look for more unified development processes, CDMOs have several high-impact growth opportunities to explore:
- Expansion into Advanced Modalities: Invest in specialized chemistry and handling capabilities for payloads like AOCs and ARCs to meet emerging demand.
- End-to-end Antibody-to-vial Integration: Use acquisitions or alliances to reduce supply chain fragmentation and support clients’ fast-track-to-market strategies.
- Regionally Anchored, Digitally Enabled Networks: Establish strong manufacturing footprints in key hubs like the United States and Europe while advancing digital integration to provide a seamless and transparent project experience.
Which of these emerging opportunities will have the maximum impact on your organization, and how will you measure it?
What’s Next for ADC CDMOs?
The future of ADC manufacturing will be driven by CDMOs that combine scientific innovation with integrated operations and a strong global presence. As sponsors demand faster timelines and higher reliability, CDMOs that offer differentiated platforms, end-to-end antibody-to-vial services, and digitally connected manufacturing environments will stand out as industry leaders.
What steps will your organization take to navigate this landscape and secure the right partnerships for long‑term success?
Frequently Asked Questions (FAQs)
What is ADC in CDMO?
ADC in the context of a CDMO refers to antibody-drug conjugates being developed and manufactured by a Contract Development and Manufacturing Organization. CDMOs provide end-to-end services, including antibody production, payload synthesis, conjugation, testing, and final formulation, helping pharmaceutical companies bring complex ADC therapies to market efficiently.
What is an antibody-drug conjugate or ADC?
An antibody-drug conjugate (ADC) is a precision oncology therapy that combines a targeted monoclonal antibody with a potent chemical payload. The antibody delivers the payload directly to cancer cells, minimizing damage to healthy tissue and making the treatment highly selective and effective.
Who is the biggest CDMO?
According to Frost & Sullivan’s Frost Radar™: Antibody-drug Conjugate Contract Development and Manufacturing Organizations, some of the biggest global CDMOs include Lonza, Catalent, Samsung Biologics, and more. These companies provide broad development and manufacturing services across biologics, small molecules, and advanced modalities, including ADCs.
What is a contract development and manufacturing organization (CDMO)?
A CDMO is a company that provides contracted services for the development, manufacturing, and sometimes testing of pharmaceutical products. They help pharma and biotech companies accelerate drug development, scale production, and maintain regulatory compliance while avoiding the need to build in-house capabilities, which is especially important for complex therapies like ADCs.
Ready to Lead the Transformation?
- Book a Growth Strategy Session: Align your growth roadmap with Frost & Sullivan’s visionary Growth Pipeline™ Dialog.
- Engage with Growth Experts: Co-design AI-enabled, data-driven operating models that scale industry-specific and commercial impact.
- Share Your Transformation Story: Position your organization as a transformation leader through Frost & Sullivan’s Transformational Growth Leadership platform.
- Join the Growth Council: Collaborate with industry leaders shaping the future of your ecosystem.
- Nominate for the Best Practices Recognition: Be recognized for excellence in growth strategy, execution, and customer impact.
- Demonstrate Industry Positioning on the Frost Radar™: Benchmark your growth performance and innovation strength against industry competitors.
- Activate Brand & Demand Growth: Accelerate awareness, engagement, and revenue growth through integrated brand and demand generation strategies.
